Literature DB >> 26160049

Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy.

Maria Messina1, Claudia Ariaudo1, Loredana Praticò Barbato2, Silvia Beltramo3, Gianna Mazzucco4, Antonio Amoroso2, Andrea Ranghino1, Vincenzo Cantaluppi5, Fabrizio Fop1, Giuseppe Paolo Segoloni1, Luigi Biancone6.   

Abstract

BACKGROUND: The C1q-binding properties of donor specific antibodies (DSA) may be related to antibody-mediated rejection and poor outcome.
METHODS: We retrospectively studied 35 kidney transplant recipients with transplant glomerulopathy (TG) and de novo DSA (dnDSA). C1q dnDSA were measured in the serum stored at renal biopsy and the association among C1q-fixing dnDSA, C4d deposition and graft loss was examined.
RESULTS: Of the 35 patients with dnDSA and TG, 15 (42.9%) had C1q-positive dnDSA and 20 (57.1%) had C1q-negative dnDSA. Ten out of 15 patients with C1q-positive dnDSA (66.6%) and 5 with C1q-negative dnDSA (25%) had C4d positive staining renal biopsies (P=0.02), being the C1q-negative dnDSA/C4d-negative TG 42.9% of the total. The C1q-positive dnDSA group has significantly higher IgG DSA Class II MFI than the C1q-negative dnDSA group (P=0.004). Patients with C4d deposits have significantly higher IgG DSA MFI for both Class I and Class II than those without C4d deposits (P=0.02). We found a trend toward higher graft loss in the C1q-positive dnDSA group (60%) versus the C1q-negative dnDSA group (40%) without a statistical significance (P=0.31).
CONCLUSION: Our study provides further characterization of TG associated with dnDSA. The major part of dnDSA-associated TG was C1q-negative and the presence of C1q-fixing dnDSA did not significantly correlate with graft outcome.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody mediated rejection; Complement; Donor specific antibodies; Kidney transplantation; Transplant glomerulopathy

Mesh:

Substances:

Year:  2015        PMID: 26160049     DOI: 10.1016/j.trim.2015.06.002

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

Review 1.  Proteomics for rejection diagnosis in renal transplant patients: Where are we now?

Authors:  Wilfried Gwinner; Jochen Metzger; Holger Husi; David Marx
Journal:  World J Transplant       Date:  2016-03-24

2.  Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients.

Authors:  Rachel M Engen; Giulia E Park; Cooper S Schumacher; Idoia Gimferrer; Paul Warner; Laura S Finn; Noel S Weiss; Jodi M Smith
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

3.  Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results.

Authors:  Alberto Mella; Ester Gallo; Maria Messina; Cristiana Caorsi; Antonio Amoroso; Paolo Gontero; Aldo Verri; Francesca Maletta; Antonella Barreca; Fabrizio Fop; Luigi Biancone
Journal:  World J Transplant       Date:  2018-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.